Protein A perfusion and post perfusion drug infusion
US5091091A · kind A · utility
Inventor
Key dates
| Filing date | Aug 6, 1990 |
| Grant date | Feb 25, 1992 |
| Priority date | — |
| Expiry date | Aug 6, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is extracorporeal plasma perfusion over a therapeutic immobilized protein A (staphylococcal), SPA. The perfused plasma is returned to the host or can be taken off one person and used to treat another and stored in perfused plasma banks. Immobilized protein A quantities, volumes of plasma perfused and the rate of administration based on clinical and toxicity evaluations are set forth. A non-toxic drug infusion during the immediate postperfusion period obtains an observed tumoricidal response far exceeding those due to the extracorporeal plasma perfusion or drug infusion alone representing an in vivo synergism between the perfused plasma and the drug. Also disclosed are the therapeutic protein A cartridge, its loading and delivery system, and a miniaturized immunoabsorbent apparatus enabling the processing of serum samples for testing small quantities of plasma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.